Fabrice Jardin

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi Follicular lymphoma without t(14;18) and with BCL-6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics
    F Jardin
    Department of Haematology and EMI 9906-IRFMP No. 23, Centre Henri Becquerel, Rouen, France
    Leukemia 16:2309-17. 2002
  2. ncbi Follicle center lymphoma is associated with significantly elevated levels of BCL-6 expression among lymphoma subtypes, independent of chromosome 3q27 rearrangements
    F Jardin
    Department of Haematology and EMI 9906-IRFMP No. 23, Centre Henri Becquerel, Rouen, France
    Leukemia 16:2318-25. 2002
  3. ncbi Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-Hodgkin B-cell lymphoma
    Fabrice Jardin
    Department of Haematology, Centre Henri Becquerel, 76000 Rouen, France
    Blood 102:1872-6. 2003
  4. ncbi Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease
    F Jardin
    INSERM, U918, European Institute of Peptide Research IFR23, Centre Henri Becquerel, Rouen, France
    Leukemia 23:698-707. 2009
  5. ncbi Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas
    Fabrice Jardin
    Department of Hematology, Centre Henri Becquerel, 76000 Rouen, France
    Haematologica 93:543-50. 2008
  6. ncbi Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value
    Fabrice Jardin
    Inserm U918, Centre Henri Becquerel and European Institute of Peptide Research IFR23, Rouen, France
    Br J Haematol 146:607-18. 2009
  7. ncbi Intense paraneoplastic neutrophilic leukemoid reaction related to a G-CSF-secreting lung sarcoma
    Fabrice Jardin
    Department of Haematology and EMI 9906, IFRMP 23, Centre Henri Becquerel, Rouen, France
    Am J Hematol 80:243-5. 2005
  8. ncbi Concomitant eosinophilia, fasciitis, and mycosis fungoides-like reaction with antinuclear autoantibodies in chronic myeloid leukaemia: role of a T-cell clone induced by imatinib
    Fabrice Jardin
    Department of Haematology, Centre Henri Becquerel, Rouen, France
    Lancet Oncol 6:728-9. 2005
  9. ncbi Clinical and biological relevance of single-nucleotide polymorphisms and acquired somatic mutations of the BCL6 first intron in follicular lymphoma
    F Jardin
    Department of Clinical Hematology, Centre Henri Becquerel, Rouen, France
    Leukemia 19:1824-30. 2005
  10. ncbi Targeted somatic mutation of the BCL6 proto-oncogene and its impact on lymphomagenesis
    Fabrice Jardin
    Département d Hématologie Clinique and Groupe d étude des proliférations lymphoïdes, Centre Henri Becquerel, Rouen, France
    Hematology 10:115-29. 2005

Collaborators

Detail Information

Publications36

  1. ncbi Follicular lymphoma without t(14;18) and with BCL-6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics
    F Jardin
    Department of Haematology and EMI 9906-IRFMP No. 23, Centre Henri Becquerel, Rouen, France
    Leukemia 16:2309-17. 2002
    ..This study indicates that 3q27(+) FL without t(14;18) translocation have peculiar clinico-pathologic features and may correspond to a rare and distinct subtype of lymphoma originating from the germinal center...
  2. ncbi Follicle center lymphoma is associated with significantly elevated levels of BCL-6 expression among lymphoma subtypes, independent of chromosome 3q27 rearrangements
    F Jardin
    Department of Haematology and EMI 9906-IRFMP No. 23, Centre Henri Becquerel, Rouen, France
    Leukemia 16:2318-25. 2002
    ..Clinical implication and alternative deregulation pathways of BCL-6 expression remain to be determined...
  3. ncbi Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-Hodgkin B-cell lymphoma
    Fabrice Jardin
    Department of Haematology, Centre Henri Becquerel, 76000 Rouen, France
    Blood 102:1872-6. 2003
    ..Junctional sequences indicate translocation origins from earlier BCL-6 mutations and switch recombinase events...
  4. ncbi Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease
    F Jardin
    INSERM, U918, European Institute of Peptide Research IFR23, Centre Henri Becquerel, Rouen, France
    Leukemia 23:698-707. 2009
    ..Taken together, these results indicate that in addition to frequent G1/S checkpoint alterations, various genetic events could contribute to the chemoresistance of the tumour...
  5. ncbi Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas
    Fabrice Jardin
    Department of Hematology, Centre Henri Becquerel, 76000 Rouen, France
    Haematologica 93:543-50. 2008
    ..We developed a polymerase chain reaction assay to provide information regarding gains or losses of relevant genes and prognosis in diffuse large B-cell lymphomas...
  6. ncbi Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value
    Fabrice Jardin
    Inserm U918, Centre Henri Becquerel and European Institute of Peptide Research IFR23, Rouen, France
    Br J Haematol 146:607-18. 2009
    ....
  7. ncbi Intense paraneoplastic neutrophilic leukemoid reaction related to a G-CSF-secreting lung sarcoma
    Fabrice Jardin
    Department of Haematology and EMI 9906, IFRMP 23, Centre Henri Becquerel, Rouen, France
    Am J Hematol 80:243-5. 2005
    ..Adjunction of the patient's serum to CD34+ cell cultures induced a 12.3-fold increase in CD15+ cells, demonstrating the serum's capacity to induce myeloid differentiation...
  8. ncbi Concomitant eosinophilia, fasciitis, and mycosis fungoides-like reaction with antinuclear autoantibodies in chronic myeloid leukaemia: role of a T-cell clone induced by imatinib
    Fabrice Jardin
    Department of Haematology, Centre Henri Becquerel, Rouen, France
    Lancet Oncol 6:728-9. 2005
  9. ncbi Clinical and biological relevance of single-nucleotide polymorphisms and acquired somatic mutations of the BCL6 first intron in follicular lymphoma
    F Jardin
    Department of Clinical Hematology, Centre Henri Becquerel, Rouen, France
    Leukemia 19:1824-30. 2005
    ..This study demonstrates that the first BCL6 intron is a highly variable region as a consequence of both SNP and SM, which may contribute to biology and outcome of FL...
  10. ncbi Targeted somatic mutation of the BCL6 proto-oncogene and its impact on lymphomagenesis
    Fabrice Jardin
    Département d Hématologie Clinique and Groupe d étude des proliférations lymphoïdes, Centre Henri Becquerel, Rouen, France
    Hematology 10:115-29. 2005
    ..These findings to date reveal several mechanisms which can influence specific mutations targeting BCL6, and which may contribute to lymphomagenesis by dysregulating control of BCL6 expression...
  11. ncbi [Auto-immune manifestations in Non-Hodgkin's lymphoma]
    F Jardin
    Département d hématologie clinique et groupe d étude des syndromes lymphoprolifératifs, Inserm U164, Centre Henri Becquerel, 76000 Rouen, France
    Rev Med Interne 26:557-71. 2005
    ..So far, rituximab has been successfully used in mixed cryoglobulinemia and cold agglutinins secondary to NHL...
  12. ncbi Intravascular large B-Cell lymphoma with bone marrow involvement and superior sagittal sinus thrombosis: report of a case successfully treated with a CHOP/rituximab combination regimen
    Fabrice Jardin
    Department of Hematology, Centre Henri Becquerel and Charles Nicolle University Hospital, Rouen, France
    Clin Lymphoma 6:46-9. 2005
    ..This observation highlights an unusual vascular aspect of ILBCL and the efficacy of the current standard treatment for this age group (CHOP/rituximab) in this particularly aggressive lymphoma subtype...
  13. ncbi The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis
    Fabrice Jardin
    Département d hématologie clinique, Centre Henri Becquerel, Rouen, France
    Pathol Biol (Paris) 55:73-83. 2007
    ....
  14. ncbi Development of autoimmunity in lymphoma
    Fabrice Jardin
    Department of Hematology, Centre Henri Becquerel, 76000 Rouen, France
    Expert Rev Clin Immunol 4:247-66. 2008
    ..Monoclonal antibodies (including rituximab, Campath-1H or epratuzumab) constitute the most promising approach to treat lymphoma-related immune disorders...
  15. ncbi Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study
    Fabrice Jardin
    Service d Hématologie and INSERM UMR918, Centre Henri Becquerel, University of Rouen, Rue d Amiens, Rouen, France
    Blood 116:1092-104. 2010
    ..Detection of TP53 and CDKN2A loss by QMPSF is a powerful tool that could be used for patient stratification in future clinical trials...
  16. ncbi Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes
    Suzan Guney
    Inserm U918, Groupe d étude des Proliférations Lymphooedes, Institut Federatif de Recherches Multidisciplinaires sur les Peptides 23 IFRMP23, Rouen, France
    Genes Chromosomes Cancer 51:858-67. 2012
    ..085). Low mRNA expression levels of these genes were correlated with the ABC phenotype. Furthermore, our results show that an inactivating methylation was more frequent in the GCB phenotype...
  17. ncbi Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma
    Hélène Lanic
    UMR INSERM U918, Centre Henri Becquerel, Rouen, France
    Leuk Lymphoma 53:34-42. 2012
    ..Our study suggests that the combination of GEP, aaIPI and interim PET more accurately predicts DLBCL prognosis and is therefore suitable for tailoring therapeutic strategies...
  18. ncbi S(mu) mutation patterns suggest different progression pathways in follicular lymphoma: early direct or late from FL progenitor cells
    Philippe Ruminy
    Inserm U918, Groupe d étude des Proliférations Lymphoïdes, Institut Federatif de Recherches Multidisciplinaires sur les Peptides 23 IFRMP23, France
    Blood 112:1951-9. 2008
    ..The second was indirect, arising from earlier subclones usually after years of remission. A better understanding of these mechanisms might influence the future choice of treatment strategies...
  19. ncbi Recurrent disruption of the Imu splice donor site in t(14;18) positive lymphomas: a potential molecular basis for aberrant downstream class switch recombination
    Philippe Ruminy
    Groupe d étude des Proliférations Lymphoïdes, Centre Henri Becquerel, INSERM U614, IFR23, 76000 Rouen, France
    Genes Chromosomes Cancer 46:735-44. 2007
    ..In conclusion, our data suggest that an acquired mutation at the splicing donor site of the Smu transcripts may participate in the selection of lymphoma cells and play a significant role during the onset of the disease...
  20. ncbi Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas
    Suzan Guney
    Inserm U918, Groupe d étude des Proliférations Lymphodes, Institut Federatif de Recherches Multidisciplinaires sur les Peptides 23 IFRMP23, Rouen, France
    Genes Chromosomes Cancer 50:715-25. 2011
    ....
  21. ncbi Eosinophilic leukemia associated with t(2;5)(p23;q31)
    Stephane Lepretre
    Department of Haematology, Centre Henri Becquerel, Rue d Amiens, 76038 Rouen Cedex, France
    Cancer Genet Cytogenet 133:164-7. 2002
    ..Initial data could suggest a clonal eosinophilia, with an hepatosplenomegaly, severe pancytopenia, and a high level of blood and medullar eosinophilia...
  22. ncbi Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness
    Philippe Bertrand
    INSERM EMI 9906 IFR23, Molecular Biology Laboratory, Department of Hematology, Centre Henri Becquerel, Rue d Amiens, 76038 Rouen Cedex, France
    Int J Cancer 113:207-12. 2005
    ..Conversely, HA overexpression in high-grade lymphomas is in favor of its involvement in tumor development and could provide a useful target for lymphoma therapy using HA-binding peptides...
  23. ncbi Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial
    Frederic Peyrade
    Department of Onco Hematology, Centre régional de lutte contre le cancer de Nice, Nice, France
    Lancet Oncol 12:460-8. 2011
    ....
  24. ncbi Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma?
    Pierre Vera
    Department of Nuclear Medicine, Henri Becquerel Centre and Rouen University Hospital, 1 rue d Amiens, Rouen, France
    Eur J Nucl Med Mol Imaging 34:1943-52. 2007
    ..In patients with lymphoma, we investigated the impact of contrast-enhanced CT on PET attenuation correction in lesions and normal tissues, particularly when PET/CT was performed after chemotherapy...
  25. ncbi Influence of PET/CT on radiologists and contrast-enhanced CT on nuclear medicine physicians in patients with lymphoma
    M J Ouvrier
    Department of Nuclear Medicine, Henri Becquerel Centre, Rouen, France
    Q J Nucl Med Mol Imaging 55:324-33. 2011
    ..We assessed in this study the influence of contrast-enhanced CT (ceCT) on PET/CT interpretation and PET/CT on ceCT interpretation in patients with lymphoma, before and after chemotherapy...
  26. ncbi Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas
    P Bertrand
    Groupe d étude des Proliférations Lymphoïdes, Centre Henri Becquerel, INSERM U614, IFRMP23, Rouen, France
    Leukemia 21:515-23. 2007
    ..006). These results suggest that these rearrangements are the consequence of a non-random process targeting MYC together with non-IG genes involved in lymphocyte differentiation and lymphoma progression...
  27. ncbi High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
    Arnaud Jaccard
    Department of Hematology, Centre Hospitalier Universitaire, Université et Centre National de la Recherche Scientifique, UMR 6101, Limoges, France
    N Engl J Med 357:1083-93. 2007
    ....
  28. ncbi Distribution of BCL2 breakpoints in follicular lymphoma and correlation with clinical features: specific subtypes or same disease?
    G Buchonnet
    INSERM, EMI 9906, IFRMP No 23, Centre Henri Becquerel, Rouen, France
    Leukemia 16:1852-6. 2002
    ..It was not possible, in this series, to demonstrate any correlation between breakpoint location and either initial characteristics of the disease or survival of the patients...
  29. ncbi Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia
    Mikael Daouphars
    Department of Pharmacy, Cancer Centre Henri Becquerel, Rouen, France
    Pharmacotherapy 33:152-6. 2013
    ..To develop and validate a self-assessment adherence tool for imatinib in patients with chronic myeloid leukemia (CML), and to correlate the use of this tool with response to treatment and adverse effects...
  30. ncbi Two patterns of chromosomal breakpoint locations on the immunoglobulin heavy-chain locus in B-cell lymphomas with t(3;14)(q27;q32): relevance to histology
    P Ruminy
    , Centre Henri Becquerel, INSERM U614, IFR23, Rouen, France
    Oncogene 25:4947-54. 2006
    ....
  31. ncbi [Primary pleural lymphoma after collapse therapy: modern aspects of an historic disease]
    F Jardin
    Service d Hematologie Clinique, centre de lutte contre le cancer Henri Becquerel, Rouen, France
    Rev Med Interne 20:985-91. 1999
    ..Most cases have been described by Japanese investigators and it seems rare or unrecognised in Western countries. We report the study of six cases observed in a single institution...
  32. ncbi Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old
    Antoine Italiano
    Haematologica 90:1281-3. 2005
    ..We show here that addition of rituximab to reduced-dose CHOP chemotherapy seems to be a good compromise between toxicity and efficacy, allowing clinicians to treat very elderly patients with a curative intent...
  33. ncbi [Clinical application of gene-expression profiling in lymphome]
    Fabrice Jardin
    Med Sci (Paris) 20:848-50. 2004
  34. ncbi Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype
    Bruno Petitjean
    , , AP-HP, , France
    Am J Surg Pathol 26:724-32. 2002
    ..Moreover, we show that this lymphoma entity likely originates from B cells at a late stage of differentiation and occasionally shares an aberrant dual B/T phenotype...
  35. ncbi Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?
    Andres J M Ferreri
    J Clin Oncol 26:5134-6; author reply 5136-7. 2008
  36. ncbi Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method
    Nathalie Gachard
    Laboratoire d Hematologie, CHU Dupuytren, Faculté de Médecine de Limoges, Universite de Limoges, Centre National de Recherche Scientifique, UMR CNRS 6101, France
    Haematologica 93:215-23. 2008
    ..Flow cytometry allows specific assessment of the expression of ZAP-70, a promising new prognostic factor in B-cell chronic lymphocytic leukemia (B-CLL), but suffers from a lack of multicenter standardization...